<DOC>
	<DOC>NCT02731131</DOC>
	<brief_summary>This single-center, randomized, open-label, pilot study is designed to evaluate the efficacy and safety of 48 weeks of treatment with peginterferon alfa-2a alone versus in combination with ribavirin in participants with CHD.</brief_summary>
	<brief_title>A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Positive hepatitis B surface antigen (HBsAg) for the prior 6 months Positive antidelta for the prior 3 months Positive HDV RNA at Screening Elevated ALT (1 to 10 times upper limit of normal) prior to first dose Chronic, necroinflammatory hepatitis documented within the prior 18 months (noncirrhotic) or 30 months (cirrhotic) Negative pregnancy and adequate contraceptive use Antiviral therapy for CHD within previous 3 months Positive for hepatitis A or C, or human immunodeficiency virus (HIV) Increased risk of metabolic liver disease Decompensated liver disease Elevated bilirubin Poor hematologic or renal function Drug/alcohol abuse within 1 year prior to study History of significant psychiatric, autoimmune, pulmonary, cardiac, oncologic, or thyroid disease Organ transplantation with existing functional graft Retinopathy or other ophthalmologic complication of diabetes or hypertension Inclusion in another investigational trial within previous 12 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>